ADV初治耐药与LAM耐药者再耐药时HBV-RT区的变异特征

表1 两组耐药患者RT区变异模式 n(%)

	ADV初治组	LAM耐药组
rtA181V	16(21.92)	5(14.71)
rtA181T	11(15.07)	7(20.58)
rtN236T	14(19.18)	0(0)
rtA181V+rtN236T	8(10.96)	2(5.88)
rtA181T+rtN236T	20(27.39)	0(0)
rtA181V+rtN236T+rtM204V	0(0)	1(2.94)
rtA181V+rtM204I±tL180M	0(0)	3(8.82)
rtA181V+rtM204V+tL180M	0(0)	1(2.94)
rtA181T+rtM204I±tL180M	0(0)	5(14.71)
rtN236T+rtM204I	0(0)	2(5.88)
rtA181S/C+rtM204I/V±tL180M	0(0)	2(5.88)
rtV214I/A+rtM204I	2(2.74)	1(2.94)
rtQ215H+rtM204V+tL180M	0(0)	1(2.94)
rtH/N238S/T/R/A/K+rtM204I/V±tL180M	2(2.74)	4(11.76)

表2 两组患者ADV耐药变异

	ADV初治组n(%)	LAM耐药组n(%)	P值
rtA181T/V	27(36.99)	21(61.76)
rtN236T	14(19.18)	2(5.88)
rtA181T/V+rtN236T	28(38.36)	3(8.82)	10.0026
无rtA181T/V和rtN236T的其他变异	4(5.48)	8(23.53)		20.0004

¹P<0.01 vs rtA181T/V, rtN236T;

²P<0.01 vs rtA181T/V, rtN236T及其他变异.